Vor Biopharma (NASDAQ:VOR) Director Sells $858,840.44 in Stock

Key Points

• Ra Capital Management, L.P. sold 53,644 Vor Biopharma shares on April 15 at $16.01 for $858,840; after the trade it directly owns 3,197,619 shares (~$51.19M), and the sale was part of a string of early‑April dispositions totaling roughly $28 million.
• VOR traded down 1.7% to $15.60 on Wednesday with about 880,470 shares changing hands; the company has a market cap of ~$762M, a 50‑day SMA of $14.53, a 200‑day SMA of $16.69, and a 1‑year range of $2.62–$65.80.
• MarketBeat shows a consensus rating of Moderate Buy with a consensus target of $50.56, though analyst views vary from sell to strong buy (e.g., Jefferies buy $50, Wedbush neutral $15).

Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report) Director Ra Capital Management, L.P. sold 53,644 shares of the firm's stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $16.01, for a total transaction of $858,840.44. Following the transaction, the director directly owned 3,197,619 shares of the company's stock, valued at $51,193,880.19. The trade was a 1.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Tuesday, April 14th, Ra Capital Management, L.P. sold 153,735 shares of Vor Biopharma stock. The shares were sold at an average price of $15.97, for a total transaction of $2,455,147.95.
• On Friday, April 10th, Ra Capital Management, L.P. sold 828 shares of Vor Biopharma stock. The shares were sold at an average price of $15.75, for a total transaction of $13,041.00.
• On Thursday, April 9th, Ra Capital Management, L.P. sold 135,201 shares of Vor Biopharma stock. The shares were sold at an average price of $16.59, for a total transaction of $2,242,984.59.
• On Wednesday, April 8th, Ra Capital Management, L.P. sold 484,104 shares of Vor Biopharma stock. The shares were sold at an average price of $16.48, for a total transaction of $7,978,033.92.
• On Monday, April 6th, Ra Capital Management, L.P. sold 589,257 shares of Vor Biopharma stock. The shares were sold at an average price of $16.59, for a total transaction of $9,775,773.63.
• On Thursday, April 2nd, Ra Capital Management, L.P. sold 260,000 shares of Vor Biopharma stock. The shares were sold at an average price of $18.23, for a total transaction of $4,739,800.00.

Vor Biopharma Trading Down 1.7%

VOR traded down $0.27 during trading on Wednesday, hitting $15.60. 880,470 shares of the company traded hands, compared to its average volume of 1,019,621. The company has a market cap of $762.06 million, a PE ratio of -0.04 and a beta of 1.92. The stock's 50-day simple moving average is $14.53 and its two-hundred day simple moving average is $16.69. Vor Biopharma Inc. has a 1 year low of $2.62 and a 1 year high of $65.80.

Hedge Funds Weigh In On Vor Biopharma

Institutional investors and hedge funds have recently made changes to their positions in the business. Ariose Capital Management Ltd purchased a new position in shares of Vor Biopharma in the 3rd quarter worth $5,368,000. Fcpm Iii Services B.V. purchased a new position in shares of Vor Biopharma during the 3rd quarter worth about $18,496,000. Susquehanna Portfolio Strategies LLC purchased a new position in shares of Vor Biopharma during the 4th quarter worth about $134,000. XTX Topco Ltd purchased a new position in shares of Vor Biopharma during the 2nd quarter worth about $66,000. Finally, Goldman Sachs Group Inc. boosted its stake in shares of Vor Biopharma by 218.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company's stock worth $61,000 after purchasing an additional 58,247 shares during the period. 97.29% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms recently weighed in on VOR. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Vor Biopharma in a research note on Wednesday, January 21st. Wedbush lifted their price objective on shares of Vor Biopharma to $15.00 and gave the stock a "neutral" rating in a research note on Tuesday, March 31st. Wells Fargo & Company assumed coverage on shares of Vor Biopharma in a research note on Thursday, March 19th. They issued an "overweight" rating and a $30.00 price objective for the company. Jefferies Financial Group assumed coverage on shares of Vor Biopharma in a research note on Monday, March 30th. They issued a "buy" rating and a $50.00 price objective for the company. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Vor Biopharma from $43.00 to $40.00 and set an "overweight" rating for the company in a research note on Friday, December 19th. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Vor Biopharma currently has a consensus rating of "Moderate Buy" and a consensus target price of $50.56.

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company's proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient's immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.